UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Jenni Björnulfson has been appointed new Chief Financial Officer (CFO) of LIDDS AB succeeding Anja Peters, who will leave LIDDS at the end of 2021. Jenni Björnulfson has over 20 years of experience from the health care sector and financial markets and will assume her new role on Dec 1, 2021 at the latest.
“I am very pleased to have Jenni on board. LIDDS is in a growth and expansion momentum and with Jenni’s extensive experience in finance I am convinced that she will be able to contribute on many levels including but not limited to financial control and investor relations”. said Nina Herne, CEO of LIDDS. “I would also like to express my gratitude to Anja Peters who as interim CFO has navigated LIDDS financially through an important period. Amongst all she has been vital in the preparations for the move from First North to the main market. I would like to wish her the best of luck in her future ventures.”
Jenni has a strong financial and industrial background and has worked for many years within the health care sector. Previous positions include being CFO for Promore Pharma and Cinclus Pharma Holding. Prior to that Jenni worked as an equity analyst at ABG Sundal Collier and she has held corporate finance positions at Alfred Berg and Handelsbanken. She holds a master’s degree in Managerial Economics and Finance from Stockholm School of Economics.
“I am delighted to have been appointed as new CFO for LIDDS and look forward to contributing to the company’s future growth and development and being part of the company’s move to the main market”, commented Jenni Björnulfson.
For more information, please contact:
Nina Herne, CEO, Phone: +46 (0)70-714 74 57, Email: firstname.lastname@example.org
LIDDS AB is required to disclose this information pursuant to Nasdaq First North Growth Market – Rulebook. The information was submitted for publication, through the agency of the aforementioned contact person, on June 1, 2021 at 08:45 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. RRedeye AB, email@example.com, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.